- New Zealand
- /
- Pharma
- /
- NZSE:BLT
Are BLIS Technologies Limited's (NZSE:BLT) Mixed Financials Driving The Negative Sentiment?
It is hard to get excited after looking at BLIS Technologies' (NZSE:BLT) recent performance, when its stock has declined 25% over the past three months. It is possible that the markets have ignored the company's differing financials and decided to lean-in to the negative sentiment. Fundamentals usually dictate market outcomes so it makes sense to study the company's financials. Particularly, we will be paying attention to BLIS Technologies' ROE today.
ROE or return on equity is a useful tool to assess how effectively a company can generate returns on the investment it received from its shareholders. Simply put, it is used to assess the profitability of a company in relation to its equity capital.
How Is ROE Calculated?
ROE can be calculated by using the formula:
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity
So, based on the above formula, the ROE for BLIS Technologies is:
6.8% = NZ$838k ÷ NZ$12m (Based on the trailing twelve months to March 2025).
The 'return' refers to a company's earnings over the last year. One way to conceptualize this is that for each NZ$1 of shareholders' capital it has, the company made NZ$0.07 in profit.
View our latest analysis for BLIS Technologies
What Has ROE Got To Do With Earnings Growth?
Thus far, we have learned that ROE measures how efficiently a company is generating its profits. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Generally speaking, other things being equal, firms with a high return on equity and profit retention, have a higher growth rate than firms that don’t share these attributes.
BLIS Technologies' Earnings Growth And 6.8% ROE
At first glance, BLIS Technologies' ROE doesn't look very promising. Yet, a closer study shows that the company's ROE is similar to the industry average of 6.8%. Having said that, BLIS Technologies' net income growth over the past five years is more or less flat. Remember, the company's ROE is not particularly great to begin with. So that could also be one of the reasons behind the company's flat growth in earnings.
As a next step, we compared BLIS Technologies' net income growth with the industry and were disappointed to see that the company's growth is lower than the industry average growth of 8.9% in the same period.
Earnings growth is a huge factor in stock valuation. What investors need to determine next is if the expected earnings growth, or the lack of it, is already built into the share price. This then helps them determine if the stock is placed for a bright or bleak future. One good indicator of expected earnings growth is the P/E ratio which determines the price the market is willing to pay for a stock based on its earnings prospects. So, you may want to check if BLIS Technologies is trading on a high P/E or a low P/E, relative to its industry.
Is BLIS Technologies Efficiently Re-investing Its Profits?
BLIS Technologies doesn't pay any regular dividends, meaning that the company is keeping all of its profits, which makes us wonder why it is retaining its earnings if it can't use them to grow its business. It looks like there might be some other reasons to explain the lack in that respect. For example, the business could be in decline.
Summary
In total, we're a bit ambivalent about BLIS Technologies' performance. Even though it appears to be retaining most of its profits, given the low ROE, investors may not be benefitting from all that reinvestment after all. The low earnings growth suggests our theory correct. So far, we've only made a quick discussion around the company's earnings growth. So it may be worth checking this free detailed graph of BLIS Technologies' past earnings, as well as revenue and cash flows to get a deeper insight into the company's performance.
Valuation is complex, but we're here to simplify it.
Discover if BLIS Technologies might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NZSE:BLT
BLIS Technologies
Develops and sells healthcare products based on strains of bacteria that produce bacteriocin activity in New Zealand, Asia Pacific, Europe Middle East and Africa, and North America.
Flawless balance sheet with solid track record.
Market Insights
Community Narratives


